Comparing cancer drug effectiveness from cells to mice to man

September 6, 2017

Science is very good at determining how drugs work in experimental models. New research out of Dartmouth's Norris Cotton Cancer Center led by Alan Eastman, PhD, helps to bridge the gap when it comes to ensuring that drugs work by the same mechanism in human patients.

The study focused on the cancer drug in cell culture, animal models, and humans. With the right preclinical analysis, coupled with appropriate proof-of-concept experiments in human patients, the Eastman team was able to more precisely establish the mechanism by which gemcitabine works in cancer patients than was previously known. Such information can also be used to develop more effective gemcitabine drug combination therapies to treat cancer, and to more rationally approach clinical trial design going forward.

Eastman's research has been able to equate drug doses from laboratory models, through animal models into human patients, and in turn define preclinical conditions that are representative of what happens in the human. "Specifically, we have defined how the drug, gemcitabine, works in , mice and man, have described conditions that cause cell cycle perturbation in each , and defined the time at which most cells are arrested in the DNA synthetic phase (S phase), and therefore most susceptible to treatment with another drug that will only work in S phase," said Eastman. "Under these conditions gemcitabine can be said to sensitize cells to our other drug, a Chk1 inhibitor, and vice versa."

Their paper "Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor," which represents a vast amount of unique research across multiple cancer models— cell culture, mice, and human—has recently been published in Oncotarget.

"Few studies have ever tried to extrapolate across multiple models in this manner. Too many studies focus on preclinical models with no consideration as to whether they are relevant to the patient," said Eastman. Such information can then be used for more rational approaches to clinical trial designs that have proof-of-concept aspects to them. "The most complex part of this study was probably accruing bladder cancer patients to the proof-of-concept clinical trial. We are extremely grateful for patients who are willing to contribute tumor tissue at defined times while on therapy so that we can evaluate biological events occurring in their tumor over time and facilitate improvements in therapy."

Ongoing are already basing their schedule of drugs on the results of this study. Next steps include dissecting additional drug combinations based on the team's early results that suggest that lower doses of gemcitabine than usually prescribed might work as well in , and low dose with more frequent administration may be a better schedule of drug administration. "Scientists need to have a much better idea of how a drug works in a patient, and to not work in a lab in isolation of the clinical relevance," said Eastman. "Proof-of-concept studies are so important for development and effective therapy."

Explore further: Combining Chk1 inhibition with standard dose Gemcitabine may be safe and effective

More information: Ryan Montano et al, Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor, Oncotarget (2017). DOI: 10.18632/oncotarget.18834

Related Stories

Combining Chk1 inhibition with standard dose Gemcitabine may be safe and effective

April 20, 2015
Adding the investigational agent GDC-0425, which blocks the function of a protein called checkpoint kinase 1 (Chk1), to standard doses of the chemotherapy drug gemcitabine, was safe and yielded responses in patients with ...

New study finds two-drug combo slows advanced pancreatic cancer

April 3, 2012
The combination of the novel drug TH-302 with the standard drug gemcitabine has shown early signs of delaying the worsening of cancer in patients with advanced pancreatic cancer, a Mayo Clinic-led study has found. This was ...

Advanced soft tissue sarcomas respond to new drug GDC-0575 combined with gemcitabine

December 1, 2016
Munich, Germany: Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory but also ...

Tumor-targeting drug shows potential for treating bone cancer patients

July 12, 2017
The treatment of osteosarcoma, the most common tumor of bone, is challenging. A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential ...

Simple post-surgery step significantly reduces bladder cancer recurrence

May 15, 2017
It's just one step. Flushing the bladder with a common chemotherapy drug after a cancerous tumor is surgically removed reduces the chances of that cancer returning. Canadian and European clinical trials have proven this true ...

Combination therapy may enhance gemcitabine activity

February 28, 2012
Oncologists who treat patients with pancreatic cancer may be one step closer to understanding why gemcitabine, the only currently available treatment, works in some cases but not in others, according to a paper in Cancer ...

Recommended for you

Alternative splicing, an important mechanism for cancer

September 22, 2017
Cancer, which is one of the leading causes of death worldwide, arises from the disruption of essential mechanisms of the normal cell life cycle, such as replication control, DNA repair and cell death. Thanks to the advances ...

'Labyrinth' chip could help monitor aggressive cancer stem cells

September 21, 2017
Inspired by the Labyrinth of Greek mythology, a new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. ...

Drug combination may improve impact of immunotherapy in head and neck cancer

September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers ...

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

New kinase detection method helps identify targets for developing cancer drugs

September 21, 2017
Purdue University researchers have developed a high-throughput method for matching kinases to the proteins they phosphorylate, speeding the ability to identify multiple potential cancer drug targets.

Poliovirus therapy induces immune responses against cancer

September 20, 2017
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.